Author Miriam Toews among Manitobans named to Order of Canada
The 61-year-old Toews was one of three Manitobans among the 83 recipients of the Order of Canada announced on June 30 by Gov. Gen. Mary Simon. The governor general's website lauded Toews' 'unique ability to portray very human stories of overcoming adversity and finding meaning is a gift to her readers, and a source of inspiration to her adoring students and fans.'
Toews was raised in Steinbach and began her literary career while living in Winnipeg, before moving to Toronto in 2009.
SUPPLIED
Manitoba-born author Miriam Toews has been given Canada's highest civilian honour.
She is the author of nine books, primarily novel-length fiction, much of which is peppered with autobiographical components. Among her novels are 2004's A Complicated Kindness, winner of the Governor General's Literary Award for fiction, 2014's All My Puny Sorrows, winner of the Writers' Trust Fiction Prize, and 2018's Women Talking, which was shortlisted for the International Dublin Literary Awards and was made into an Oscar-nominated 2022 film.
Toews' next book, A Truce That Is Not Peace, is her first work of autobiographical non-fiction, and will be published on Aug. 26 by Knopf Canada.
Two Manitobans were named members of the Order of Canada: Albert Friesen, who helped build the province's biotechnology industry, and created WinRho, Canada' first biotech product; and Kathy Mulder, for her work to improve care for people with inherited bleeding disorders. She was the first woman and first Canadian to chair the World Federation of Hemophilia's Musculoskeletal Committee.
The list of appointees also includes Marc-André Blanchard, who takes over in July as Prime Minister Mark Carney's chief of staff. Blanchard previously worked as a lawyer and as Canada's ambassador and permanent representative to the United Nations.
Dr. Theresa Tam, who retired in June as Canada's chief public health officer, will be inducted as an officer of the Order of Canada. Tam became a household name as she led the country's public health response to the COVID-19 pandemic.
Dr. Bonnie Henry, who led British Columbia's pandemic response as the provincial health officer and is heading its public health response to the drug overdose crisis, joins Tam among the new appointees at the officer level.
More than 8,200 people have been appointed to the Order of Canada since its creation in 1967. Many are national household names, including politicians, musicians, actors and writers. Many others are awarded for their contributions at a more local level to multiple fields, including science, medicine, education and the arts.
The latest list includes several politicians, including former finance minister John Manley, who is being promoted to the companion level after initially being inducted as an officer of the Order of Canada in 2009.
Companion is the highest level within the order, followed by the officer level, which are both generally awarded for contributions to Canada as a whole, or 'humanity at large.'
A member of the Order of Canada recognizes distinguished service to a specific community or within a specific field.
Maureen McTeer, a lawyer and author who has worked on gender issues and health guidelines, will be appointed as an officer. McTeer, who is married to former prime minister Joe Clark, is currently a visiting professor in the faculty of common law at the University of Ottawa.
Weekly
A weekly look at what's happening in Winnipeg's arts and entertainment scene.
'We proudly recognize each of these individuals whose dedication and passion for service not only enrich our communities but also help shape the fabric of our nation,' Simon said in a statement released with the list. 'Together, they inspire us to strive for greatness and to foster a future filled with hope and possibility.'
Others appointed to the Order of Canada include biologist Ford Doolittle, musician Gilbert Donald Walsh, former senator Claudette Tardif and poet Louise Bernice Halfe, whose Cree name is Sky Dancer.
Genealogist Stephen White received an honorary appointment.
The inductees being announced Monday will be invested in ceremonies to be scheduled at a later date.
— The Canadian Press, with files from Ben Sigurdson
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
National Post
38 minutes ago
- National Post
REPEAT/Cybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible Debentures
Article content Article content – Funding agreement contemplates a conversion formula with a potential 30% premium upon conversion and positions the Company for growth, and accelerated advancement of its clinical pipeline programs, CYB003 and CYB004 – Article content Article content TORONTO — Cybin Inc. (NYSE American: CYBN) (Cboe Canada: CYBN) (' Cybin ' or the ' Company '), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce the Company has entered into a securities purchase agreement (the ' Securities Purchase Agreement ') with High Trail Special Situations LLC (' High Trail '), pursuant to which the Company agreed to sell and issue to High Trail up to US$500,000,000 in aggregate principal amount of unsecured convertible debentures (the ' Convertible Debentures '). The sale and issue of US$50,000,000 principal amount of Convertible Debentures was completed on June 30, 2025 (the ' Private Placement '). The sale and issue of US$450,000,000 of the principal amount of Convertible Debentures will be determined at a future date, upon mutual agreement of the parties. Article content 'This financing represents a major inflection point for Cybin and supports our position as a leader within our sector,' said Doug Drysdale, Chief Executive Officer of Cybin. 'High Trail Capital is an experienced investor, and its confidence and appreciation of our breakthrough clinical data and intellectual property portfolio recognize the potential of the Company. This financing comes at an opportune time for Cybin, as we advance our lead programs, CYB003 and CYB004, in Phase 3 and Phase 2, respectively. CYB003 demonstrated over 70% remission rates and continued durability over 12 months for patients with uncontrolled depression. We await the conclusion of our CYB004 Phase 2 proof-of-concept study, in patients with generalized anxiety disorder,' said Drysdale. Article content Joseph Gunnar & Co., LLC acted as the sole placement agent in connection with this transaction. Article content Pipeline Acceleration Drives Multiple Value Creation Catalysts Article content The funding will accelerate Cybin's clinical-stage programs across multiple high-value indications: Article content CYB003 Program Achievements: Article content Breakthrough Clinical Results: Unprecedented 71% remission rate in major depressive disorder at 12 months after two 16 mg doses in Phase 2 study Durability advantage: 12-month sustained efficacy demonstrating long-term therapeutic benefit FDA Recognition: Breakthrough Therapy Designation received, expediting regulatory pathway Multinational Phase 3 PARADIGM program underway Article content CYB004 Program Momentum: Article content Dual Indication Strategy: Expanding addressable market opportunity Phase 2 GAD study expected to complete around mid-year 2025 1 Article content Commercialization Infrastructure: Article content Value Catalysts Drive Sustained Momentum Article content Near-Term Catalysts: Article content CYB004 Phase 2 GAD study expected to complete around mid-2025 1 Initiation of second CYB003 pivotal study, EMBRACE, around mid-2025 1 EXTEND study initiation imminent 1 Article content Medium-Term Catalysts (2025-2026): Article content Transaction Terms Article content The Convertible Debentures have a two-year term from the closing date (the ' Term '). The Company shall pay guaranteed interest equal to 5.5% of the principal per annum for the Term. Such interest was pre-paid on closing. Upon the occurrence of an event of default, interest shall increase to a rate of 18% per annum on the outstanding principal balance. Pursuant to the terms of the Securities Purchase Agreement, the Company and High Trail may, upon mutual consent, enter into subsequent securities purchase agreements for the purchase and sale of up to an additional US$450,000,000 principal amount of Convertible Debentures, in tranches, in amounts on such dates as may be mutually agreed and each subsequent tranche shall include prepaid interest at a rate of 9.5%. Article content Subject to the terms of the Securities Purchase Agreement and the Convertible Debentures, High Trail will be entitled to convert the principal amount of, and accrued and unpaid interest, if any, on each Convertible Debenture, in whole or in part, from time to time, into common shares in the capital of the Company (the ' Common Shares ') at a conversion price per Common Share equal to the lower of (a) 130% of the volume weighted average price (' VWAP ') of the Common Shares on the day prior to the initial issuance of the Convertible Debentures, or (b) the VWAP of the Common Shares during the five trading days immediately prior to the date of conversion. Article content The Company, in its sole discretion, may prepay any outstanding amount under the Convertible Debentures, in whole or in part, in cash by providing High Trail with advance written notice prior to such prepayment. The prepayment shall include, (i) if paid during the first year after closing, a 5% prepayment premium on the amount of the prepayment or (ii) if paid thereafter, a 3% prepayment premium on the amount of the prepayment. Article content The terms of the Convertible Debentures restrict the conversion of Convertible Debentures by High Trail if such a conversion or exercise would cause High Trail, together with any affiliate thereof, to beneficially own in excess of 4.99% of the number of Common Shares outstanding immediately after giving effect to such conversion. Article content The Company intends to use the net proceeds from the Private Placement for working capital and general corporate purposes. Article content The Convertible Debentures were offered on a private placement basis pursuant to prospectus exemptions in Canada and pursuant to exemptions and exclusions from the registration requirements of the United States Securities Act of 1933, as amended, and applicable state securities laws. The Company has agreed to use commercially reasonable efforts to: (a) file a prospectus supplement to the Company's base shelf prospectus dated August 17, 2023, as amended on December 22, 2023, April 8, 2024 and January 6, 2025, with applicable Canadian securities regulators to qualify the secondary market sales of the Common Shares in the United States; and (b) either (i) prepare and file the Canadian prospectus supplement with the United States Securities and Exchange Commission, or (ii) file a prospectus supplement pursuant to General Instruction II.L of Form F-10 with the United States Securities and Exchange Commission to the Company's registration statement on Form F-10 (File No. 333-284173), which was declared effective by the SEC on January 14, 2025, or on such other form as may be available to the Company, in either case qualifying the resale of the Common Shares underlying the Convertible Debentures. Article content No securities regulatory authority has either approved or disapproved of the contents of this news release. This news release is not an offer to sell or the solicitation of an offer to buy the securities in the United States or in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to qualification or registration under the securities laws of such jurisdiction. The securities being offered have not been registered under the U.S. Securities Act, and such securities may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons absent registration or an applicable exemption from U.S. registration requirements and applicable U.S. state securities laws Article content About Cybin Article content Cybin is a late-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options to address the large unmet need for people who suffer from mental health conditions. Article content With promising proof-of-concept data, Cybin is working to change the mental health treatment landscape through the introduction of intermittent treatments that provide long lasting results. The Company is currently developing CYB003, a proprietary deuterated psilocin analog, in Phase 3 studies for the adjunctive treatment of major depressive disorder and CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule in a Phase 2 study for generalized anxiety disorder. The Company also has a research pipeline of investigational, 5-HT-receptor focused compounds. Article content Founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. For Company updates and to learn more about Cybin, visit or follow the team on X, LinkedIn, YouTube and Instagram. Article content There is no assurance that timelines will be met. Anticipated timelines regarding the initiation, advancement and results of clinical trials are based on reasonable assumptions informed by current knowledge and information available to the Company. See 'Cautionary Notes and Forward-Looking Statements'. Article content Cautionary Notes and Forward-Looking Statements Article content Certain statements in this news release constitute forward-looking information and forward-looking statements within the meaning of applicable securities laws (together, 'forward-looking statements'). Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as 'may', 'should', 'could', 'intend', 'estimate', 'plan', 'anticipate', 'expect', 'believe' or 'continue', or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the use of Private Placement proceeds; the conversion of the Convertible Debentures into Common Shares; the sale and issue of US$450,000,000 principal amount of Convertible Debentures at a future date; CYB004 Phase 2 GAD study expected to complete around mid-2025; Initiation of second CYB003 pivotal study, EMBRACE, around mid-2025; the Company's Medium-Term Catalysts for 2025-2026; Phase 3 PARADIGM program enrollment acceleration; the Company's ability to achieve commercial success; and the Company's ability to address the need for new and innovative treatment options for people who suffer from mental health conditions. Article content These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the psychedelics market; the ability of the Company to successfully achieve its business objectives; plans for growth; political, social and environmental uncertainties; employee relations; the presence of laws and regulations that may impose restrictions in the markets where the Company operates; implications of disease outbreaks on the Company's operations; and the risk factors set out in each of the Company's management's discussion and analysis for the three and nine month periods ended December 31, 2024 and the Company's annual information form for the year ended March 31, 2024, which are available under the Company's profile on and with the SEC on EDGAR at Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law. Article content Cybin makes no medical, treatment or health benefit claims about Cybin's proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds. The efficacy of such products has not been confirmed by approved research. There is no assurance that the use of psilocin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds can diagnose, treat, cure or prevent any disease or condition. Rigorous scientific research and clinical trials are needed. If Cybin cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on Cybin's performance and operations. Article content Article content Article content Article content Article content Contacts Article content Investor & Media Contact Article content : Article content
Global News
38 minutes ago
- Global News
Bid by 23andMe's former CEO to buy company given greenlight by court
Anne Wojcicki's bid to buy 23andMe, the genetic testing company she cofounded nearly 20 years ago, has received the court greenlight. That means Wojcicki's nonprofit TTAM Research Institute will purchase 'substantially all' of San Francisco-based 23andMe's assets for US$305 million. The transaction — which arrives more than three months after 23andMe filed for Chapter 11 bankruptcy — is set to officially close in the coming weeks. 'I am thrilled that TTAM will be able to build on the mission of 23andMe to help people access, understand and benefit from the human genome,' Wojcicki said in a statement Monday — later adding that, 'the future of health care belongs to all of us.' The sale, which was approved by U.S. Bankruptcy Judge Brian C. Walsh on Friday, marks the end of a monthslong bidding war between TTAM and Regeneron Pharmaceuticals — a biotech company that had previously agreed to buy most of 23andMe's assets for US$256 million in May. But Wojcicki's nonprofit later topped that offer, winning the final round of bidding held last month. Story continues below advertisement Under the deal, TTAM will acquire 23andMe's signature 'Personal Genome Service' provided through the company's saliva-based DNA testing kits — as well as research operations and its Lemonaid Health subsidiary, a telehealth services provider that 23andMe previously planned to wind down. Wojcicki had worked to take 23andMe private for some time. With the company struggling to find a profitable business model since going public in 2021, she's maintained that it would operate better outside market pressures. But that endeavor proved to be tumultuous — notably in September of last year, when all of 23andMe's independent directors resigned from its board citing a 'clear' difference of opinion with Wojcicki on the company's future following drawn-out negotiations. Get breaking National news For news impacting Canada and around the world, sign up for breaking news alerts delivered directly to you when they happen. Sign up for breaking National newsletter Sign Up By providing your email address, you have read and agree to Global News' Terms and Conditions and Privacy Policy Leading up to 23andMe's March bankruptcy filing, subsequent efforts from Wojcicki to acquire the company were unsuccessful. And when 23andMe filed for Chapter 11 in late March, Wojcicki resigned as CEO — noting at the time that she was stepping down to be 'in the best position' as an independent bidder. 1:19 23andMe lacked strong data protection allowing for breach: Canada's privacy head Now that Wojcicki's nonprofit will acquire 23andMe, it's unclear whether the co-founder will step back into the CEO seat. But despite stepping down from the top post months ago, Wojcicki has remained on the company's board throughout the bankruptcy process. Story continues below advertisement Beyond financial strains leading up to 23andMe's bankruptcy, privacy concerns related to customers' genetic information also emerged — dating back to even before the bankruptcy process with a 2023 data breach. But concern what new ownership could mean for 23andMe users' personal data has bubbled up in recent months. The genetic testing business had about 13 million customers at the time of its sale hearing, court documents note. In June, 27 states and the District of Columbia filed a lawsuit seeking to block the sale of personal genetic data by 23andMe without customer consent. And in a memorandum opinion outlining his approval 23andMe's sale to TTAM on Friday, Walsh acknowledged these states' objections to the acquisition — but that noted many had since been resolved. Still, California, Kentucky, Tennessee, Texas, and Utah 'remain actively opposed to the sale.' In a statement to Politico on Monday, California Attorney General Rob Bonta's office maintained that 23andMe's sale 'does not comply' with genetic privacy law in the state — and said it was 'disappointed' with the court's approval, adding that it was evaluating next steps. The Associated Press reached out to Bonta's office and 23andMe for further comments on Tuesday. When announcing its intended sale to Wojcicki's nonprofit last month, 23andMe confirmed that TTAM 'has affirmed its commitment' to comply with the company privacy policies and applicable law. That means TTAM will honor existing policies around consumer data, the company said, which includes allowing users to delete their data and 'opt out' of research. Story continues below advertisement All customers will be emailed at least two business days before the acquisition closes — with details on TTAM's privacy commitments and instructions on how to delete data or opt out of research, 23andMe said. The company added that TTAM will offer customers two years of Experian identity theft monitoring at no cost. 23andMe reiterated those privacy policies on Monday. And Wojcicki added that, 'Core to my beliefs is that individuals should be empowered to have choice and transparency with respect to their genetic data and have the opportunity to continue to learn about their ancestry and health risks as they wish.'
Global News
an hour ago
- Global News
Theresa Tam, Georges St-Pierre among new Order of Canada appointees
From doctors who guided Canada through the COVID-19 pandemic to a former deputy prime minister and a UFC champion, nearly seven dozen Canadians have been named to the Order of Canada. The full list was made public on Monday, a day before Canadians are set to gather for Canada Day celebrations, though Gov.-Gen. Mary Simon made the appointments on April 17, acting on recommendations of the Advisory Council of the Order. 'We proudly recognize each of these individuals whose dedication and passion for service not only enrich our communities but also help shape the fabric of our nation,' said Simon in a statement. 'Together, they inspire us to strive for greatness and to foster a future filled with hope and possibility.' Among the names, former deputy prime minister John Manley was named a companion for bridging 'private, public and not-for-profit sectors, promoting diversity and inclusiveness in leadership while engaging on matters of public policy.' Story continues below advertisement Molecular biologist W. Ford Doolittle of Halifax was also named a companion alongside Manley, the highest rank in the Order. 1:23 Throne speech: King Charles alludes to U.S.-Canada trade war, says Canadians 'anxious' about changes to global trade order Canada's former chief public health officer Dr. Theresa Tam, who completed her tenure last month, was named an officer of the Order alongside British Columbia's provincial health officer Dr. Bonnie Henry. Get daily National news Get the day's top news, political, economic, and current affairs headlines, delivered to your inbox once a day. Sign up for daily National newsletter Sign Up By providing your email address, you have read and agree to Global News' Terms and Conditions and Privacy Policy Tam's naming to the Order, according to the release of names, says her tenure was characterized 'by her commitment to health equity and highlighted by her leadership role in the country's response to the COVID-19 pandemic.' That was also echoed by Henry's description by the Order, noting her work in B.C.'s response to the pandemic, while saying she's used her 'expertise in public health and preventative medicine to safeguard the health of people in Canada and globally for decades.' Story continues below advertisement David Jones, Tam's predecessor as the first chief public health officer, was also named an officer for 'supporting and safeguarding Canadians' health,' including helping establish Canada's public health agency. Other officers appointed include lawyer and author Maureen McTeer for her work on gender issues and health guidelines, Peter Rosenbaum for transforming child disability care, and actor Tonya Williams for her advocacy for greater access and inclusion of racialized people in film and media. A total of 83 people were named to the Order of Canada on April 17, with the list released Tuesday, with two companions, 19 officers and 62 members, the latter being considered the introductory honour level in the order. According to the Governor General's office, one appointment is a promotion within the order while another is an honorary appointment. A member or an officer can be promoted to a higher level if they demonstrate 'further exceptional achievement.' 1:12 Actress Sandra Oh formally made officer of the Order of Canada Marc-André Blanchard, who is set to take over the role of chief of staff to Prime Minister Mark Carney, is among those new members to the Order for his contributions to Canada and its economic development. Story continues below advertisement Former UFC fighter Georges St-Pierre has also been named a member, with the Order of Canada citation noting his foudnation helps youth, counters bullying, promotes physical activity and provides yearly scholarships to student-athletes. Donald Campbell, who oversaw the negotiations of the North American Free Trade Agreement (NAFTA) in 1994, has also become a member for his 'stellar diplomatic career,' including as a G8 summit sherpa and senior negotiator with the U.S. Some previously named Order of Canada appointees are also expected to take the stage later on Tuesday, as Gov.-Gen. Mary Simon is set to invest a number of Canadians into the order at Canada Day festivities in Ottawa. Actor Ryan Reynolds and singer, songwriter Heather Rankin, who were appointed officers of the order in 2024, will take the stage alongside previously-announced members Deantha Rae Edmunds, Scott Oake and Kim Thúy Ly Thanh for an investiture ceremony.
